#USA #New York #healthcare #gene therapy #REGENXBIO

REGENXBIO's Upcoming Participation in a Healthcare Conference

REGENXBIO Inc. (Nasdaq: RGNX), a pioneering company in gene therapy, has announced its participation in the upcoming Piper Sandler 37th Annual Healthcare Conference. This exciting event is set to take place on December 2, 2025, at 8:30 AM ET in New York, NY. During this conference, REGENXBIO will engage in a fireside chat, which promises to highlight the company's advances in gene therapy and its impact on healthcare.

About the Conference

The Piper Sandler Healthcare Conference is a prestigious annual event that draws a wide range of healthcare professionals, investors, and innovators from across the industry. REGENXBIO’s presence at this conference underscores its commitment to sharing the latest advancements in gene therapy, a field that has the potential to transform treatment options for patients with serious diseases.

What to Expect

Attendees can expect a comprehensive discussion on REGENXBIO's innovative therapies that target rare genetic diseases and retinal disorders. Notably, the company has developed several late-stage treatments that demonstrate the transformative potential of gene therapy, including:

• - RGX-202 for Duchenne Muscular Dystrophy
• - clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II (MPS II), developed in collaboration with Nippon Shinyaku
• - RGX-111 for MPS I, also in partnership with Nippon Shinyaku
• - surabgene lomparvovec (ABBV-RGX-314) for wet age-related macular degeneration and diabetic retinopathy, in cooperation with AbbVie

The fireside chat will also cover the promising results observed in clinical trials and the company's vision for the future of gene therapy. A live webcast of this session will be available in the Investors section of REGENXBIO's website, allowing those unable to attend in person to tune in. Furthermore, an archived version of the chat will be accessible for about 30 days after the event, ensuring broad access to the insights shared.

The Mission of REGENXBIO

Established in 2009, REGENXBIO is dedicated to improving lives through the curative capabilities of gene therapy. The company has been at the forefront of adeno-associated virus (AAV) gene therapy, creating treatments that aim to change the healthcare landscape for countless individuals affected by genetic disorders. Thousands of patients have benefitted from REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®, which has become a cornerstone in treating spinal muscular atrophy.

As REGENXBIO continues its journey in developing groundbreaking therapies, its contributions to the healthcare sector are increasingly significant. The impending Piper Sandler conference serves as an excellent platform for REGENXBIO to communicate its progress and the ongoing commitment to advancing gene therapy.

For up-to-date information and insights, interested parties can visit REGENXBIO's website. Be sure to tune in for the fireside chat at the Piper Sandler Healthcare Conference, as REGENXBIO provides a glimpse into the promising future of gene therapy and its unfolding story in the realm of innovative healthcare solutions.